COVID-19: Medigen results good, experts say‘SECOND BEST’: A researcher said that as phase 3 vaccine trials could take several years, it would be best for Taiwan to use the vaccines based on the phase 2 resultsStaff writer, with CNAPhase 2 clinical trial results of a COVID-19 vaccine developed by Medigen Vaccine Biologics Corp generated good data, experts said, although they warned that there was still no way to know how effectively it would prevent the disease. “Data look quite good,” Academia Sinica researcher Michael Lai (賴明詔) said on Thursday after Medigen announced that its vaccine candidate had shown no major safety concerns. There are many ways to produce vaccines, including via protein subunits such as the one Medigen is working on, he said. It would be acceptable for Medigen to apply for EUA with only the results of its phase 2 trials, he said. Medigen said it would seek an EUA from the Food and Drug Administration as soon as possible based on the promising results from its phase 2 clinical trials.

Source: Taipei Times June 11, 2021 15:56 UTC